Showing results (11-20 of 16) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Psychopharmacology Bulletin|May 2, 1998
Initial safety, tolerability pharmacodynamics, and pharmacokinetics of CI-1007 in patients with schizophreniaJ J Sramek, M A Eldon, E Posvar, et al.Journal of Medicinal Chemistry|December 22, 1995
Identification, characterization and pharmacological profile of three metabolites of (R)-(+)-1,2,3,6-tetrahydro-4-phenyl-1-[(3-phenylcyclohexen-1- yl)methyl]pyridine (CI-1007), a dopamine autoreceptor agonist and potential antipsychotic agentJ L Wright, D M Downing, M R Feng, et al.Bioorganic & Medicinal Chemistry|July 15, 2000
The discovery of [1-(4-dimethylamino-benzyl)-piperidin-4-yl]-[4-(3,3-dimethylbutyl)-phen yl]-(3-methyl-but-2-enyl)-amine, an N-type Ca+2 channel blocker with oral activity for analgesiaL Y Hu, T R Ryder, M F Rafferty, et al.Pharmaceutical Research|March 1, 1997
Pharmacokinetics and pharmacodynamics of an investigational antipsychotic agent, CI-1007, in rats and monkeysM R Feng, A E Corbin, Y Wang, et al.Journal of Medicinal Chemistry|October 9, 1999
Synthesis of a series of 4-benzyloxyaniline analogues as neuronal N-type calcium channel blockers with improved anticonvulsant and analgesic propertiesL Y Hu, T R Ryder, M F Rafferty, et al.Drug Design and Discovery|August 6, 2000
Neuronal N-type calcium channel blockers: a series of 4-piperidinylaniline analogs with analgesic activityL Y Hu, T R Ryder, M F Rafferty, et al.Pageof 2